|79.98||+1.02||+1.29%||Vol 10.45M||1Y Perf 18.31%|
|Jun 27th, 2022 16:00 DELAYED|
|- -||-0.31 -0.39%|
|Target Price||78.18||Analyst Rating||Moderate Buy 2.15|
|Potential %||-2.25||Finscreener Ranking||★ 40.02|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 44.76|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 49.91|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★+ 42.21|
|Price Range Ratio 52W %||103.80||Earnings Rating||Sell|
|Market Cap||170.28B||Earnings Date||27th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Jul 2022|
|Estimated EPS Next Report||1.90|
|EPS Growth Next 5 Years %||6.20|
|Avg. Weekly Volume||12.25M|
|Avg. Monthly Volume||13.65M|
|Avg. Quarterly Volume||14.08M|
Bristol-Myers Squibb Company (NYSE: BMY) stock closed at 79.98 per share at the end of the most recent trading day (a 1.29% change compared to the prior day closing price) with a volume of 10.45M shares and market capitalization of 170.28B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30250 people. Bristol-Myers Squibb Company CEO is Giovanni Caforio.
The one-year performance of Bristol-Myers Squibb Company stock is 18.31%, while year-to-date (YTD) performance is 28.28%. BMY stock has a five-year performance of 43.15%. Its 52-week range is between 53.22 and 79, which gives BMY stock a 52-week price range ratio of 103.80%
Bristol-Myers Squibb Company currently has a PE ratio of 26.20, a price-to-book (PB) ratio of 4.97, a price-to-sale (PS) ratio of 3.34, a price to cashflow ratio of 10.10, a PEG ratio of 2.32, a ROA of 5.80%, a ROC of 9.09% and a ROE of 18.07%. The company’s profit margin is 13.35%, its EBITDA margin is 40.80%, and its revenue ttm is $46.96 Billion , which makes it $22.06 revenue per share.
Of the last four earnings reports from Bristol-Myers Squibb Company, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.90 for the next earnings report. Bristol-Myers Squibb Company’s next earnings report date is 27th Jul 2022.
The consensus rating of Wall Street analysts for Bristol-Myers Squibb Company is Moderate Buy (2.15), with a target price of $78.18, which is -2.25% compared to the current price. The earnings rating for Bristol-Myers Squibb Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bristol-Myers Squibb Company has a dividend yield of 2.93% with a dividend per share of $2.16 and a payout ratio of 273.00%.
Bristol-Myers Squibb Company has a Buy technical analysis rating based on Technical Indicators (ADX : 5.10, ATR14 : 1.50, CCI20 : 166.35, Chaikin Money Flow : 0.16, MACD : 0.23, Money Flow Index : 66.61, ROC : 3.09, RSI : 65.84, STOCH (14,3) : 99.45, STOCH RSI : 1.00, UO : 65.39, Williams %R : -0.55), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bristol-Myers Squibb Company in the last 12-months were: Adam Dubow (Sold 2 466 shares of value $167 441 ), Christopher S. Boerner (Option Excercise at a value of $0), Christopher S. Boerner (Sold 29 532 shares of value $2 043 525 ), David V. Elkins (Option Excercise at a value of $3 394 299), David V. Elkins (Sold 99 691 shares of value $6 674 497 ), Elizabeth A. Mily (Option Excercise at a value of $0), Giovanni Caforio (Option Excercise at a value of $0), Giovanni Caforio (Sold 150 000 shares of value $10 278 400 ), Julia A. Haller (Option Excercise at a value of $0), Karen Murphy Santiago (Option Excercise at a value of $0), Karen Murphy Santiago (Sold 6 577 shares of value $455 096 ), Paul von Autenried (Sold 76 134 shares of value $4 624 992 ), Powell Ann Judge (Option Excercise at a value of $0), Powell Ann Judge (Sold 23 280 shares of value $1 596 309 ), Rupert Vessey (Option Excercise at a value of $10 764 377), Rupert Vessey (Sold 232 952 shares of value $15 945 125 ), Samit Hirawat (Option Excercise at a value of $0), Sandra Leung (Option Excercise at a value of $0), Sandra Leung (Sold 94 390 shares of value $6 867 545 )
Mon, 02 May 2022 01:15 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Bristol Myers (BMY) and Eli Lilly & Co (LLY)- TipRanks. All rights reserved.
Tue, 26 Apr 2022 01:57 GMT Berenberg Bank Believes Bristol Myers (BMY) Still Has Room to Grow- TipRanks. All rights reserved.
Tue, 01 Mar 2022 14:41 GMT Bristol-Myers: A Long-Term Dividend Growth Stock- TipRanks. All rights reserved.
Wed, 16 Feb 2022 19:32 GMT Bristol-Myers Squibb: Deserves a Higher Valuation- TipRanks. All rights reserved.
Wed, 16 Feb 2022 07:38 GMT Bristol Myers Squibb Updates 1 Key Risk Factor- TipRanks. All rights reserved.
Thu, 10 Feb 2022 16:21 GMT Bristol-Myers Squibb: Positioned to Deliver- TipRanks. All rights reserved.
Wed, 26 Jan 2022 18:37 GMT Bristol Myers: How Much Upside Is Left- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.